An emerging role for escitalopram in the treatment of obsessive-compulsive disorder by Hedges, Dawson W & Woon, Fu Lye M
Neuropsychiatric Disease and Treatment 2007:3(4) 455–461
© 2007 Dove Medical Press Limited.  All rights reserved
455
EXPERT OPINION
An emerging role for escitalopram in the 
treatment of obsessive-compulsive disorder
Dawson W Hedges
Fu Lye M Woon
Department of Psychology and the 
Neuroscience Center Brigham Young 
University, Provo, UT, USA
Correspondence: Dawson W Hedges
Department of Psychology and the 
Neuroscience Center, Brigham Young 
University, 1001 SWKT, Brigham Young 
University, Provo, Utah, 84602, USA
Email dawson_hedges@byu.edu
Abstract: Obsessive-compulsive disorder (OCD) is a common and severe neuropsychiatric 
disorder treated by both behavioral and pharmacologic techniques. Despite the availability of 
treatments for OCD, including the selective serotonin reuptake inhibitors (SSRIs), many OCD 
patients have an inadequate response to current treatments. As such, additional approaches to the 
management of OCD are required. A potential but little studied treatment for OCD is the SSRI 
escitalopram. Escitalopram is the S-enantiomer of citalopram, the preparation containing both 
S and R enantiomers of citalopram. Not only is escitalopram the most selective of the SSRIs, 
it is also devoid of R-citalopram, which may interfere with the effects of the S enantiomer. 
Escitalopram appears to be effective in depression and several anxiety disorders, including social 
anxiety disorder and generalized anxiety disorder, conditions in which it also appears reasonably 
well tolerated. Enantiomeric speciﬁ  city, high serotonin reuptake selectivity, comparatively good 
tolerability and favorable pharmacokinetics, and preliminary evidence of efﬁ  cacy in OCD suggest 
a potential role for the use of escitalopram in the treatment of OCD. Nevertheless, additional 
work including evaluating the use of escitalopram with behavioral interventions and in long-
term treatment of OCD is needed to clarify its overall role in managing OCD. 
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Introduction to management 
of obsessive-compulsive disorder
Characterized by obsessions, compulsions, considerable functional impairment, and 
once thought to be quite rare (Abramowitz 1997), obsessive-compulsive disorder 
(OCD) may occur in up to approximately 2.4% of the population in North America 
(Karno et al 1988) and typically presents in a person’s early 20s (Abramowitz 1997). 
For many patients, OCD tends to be chronic, with many people experiencing features 
of OCD over decades (Skoog and Skoog 1999). People with OCD also suffer from a 
lower quality of life compared with healthy controls (Moritz et al 2005). Both psycho-
therapeutic and psychopharmacological approaches either singly or together are used 
in the treatment of OCD. The relationship between treatment response and quality of 
life in people with OCD is not entirely clear, but some data suggest that quality of life 
improves with treatment response (Moritz et al 2005). 
 Initially consisting of psychoanalysis, psychotherapy for OCD now uses the more 
effective exposure and response prevention techniques, cognitive therapy, or thought-
stopping approaches (Abramowitz 1997). It is unknown, however, whether exposure 
and response prevention approaches and cognitive therapy work through separate 
mechanisms or via common factors, although Abramowitz (1997) concluded that these 
two therapies work through a similar mechanism due to lack of a differential response 
between cognitive and physiological features of OCD. Nevertheless, exposure and 
response prevention treatment not only appears helpful in the short-term treatment 
of OCD, but also seems to be associated with lower relapse rates compared with Neuropsychiatric Disease and Treatment 2007:3(4) 456
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pharmacological interventions even after discontinuation 
(Simpson et al 2004). 
Until the availability of the tricyclic antidepressant 
clomipramine, pharmacotherapy resulted in little, if any, 
improvement in OCD. The efﬁ  cacy of clomipramine in 
OCD is now well established (Dell’Osso et al 2006), and 
its inhibition of serotonin reuptake guided attention to a 
possible role for serotonin in OCD (Abramowitz 1997). In 
fact, non-serotonergic antidepressants appear to have little 
efﬁ  cacy in OCD (Fallon and Mathew 2000; Dell’Osso et al 
2006). Since the introduction of clomipramine, other phar-
macological approaches to treat OCD using medication have 
developed that predominantly include the use of selective 
serotonin reuptake inhibitors (SSRIs; Starcevic 2005). A 
1997 meta-analysis comparing clomipramine with ﬂ  uoxetine 
and sertraline found larger effect sizes for clomipramine; 
however, there were relatively few studies of ﬂ  uoxetine and 
sertraline, and a large contrast in side effect proﬁ  les between 
clomipramine and placebo may have inﬂ  ated the effect size 
for clomipramine (Abramowitz 1997). More recently, other 
work also has found that clomipramine tends to be slightly 
superior to other SSRIs in OCD (Ackerman and Greenland 
2002; Dell’Osso et al 2006). Using meta-regression to control 
for factors such as clinical-trial length and OCD severity in 
their meta-analysis of placebo-controlled trials of clomip-
ramine, ﬂ  uvoxamine, sertraline, and paroxetine, Ackerman 
and Greenland (2002) found superiority for clomipramine. 
Monoamine oxidase inhibitors may have limited efﬁ  cacy in 
OCD and a controlled, 6-week trial of buspirone suggested 
efﬁ  cacy in OCD (Fallon and Mathew 2000). In a double-
blind, placebo-controlled, multiple-crossover trial compar-
ing clomipramine, clonazepam, and clonidine against each 
other in 6-week-long trials for the treatment of OCD, both 
clomipramine and clonazepam were effective in reducing 
symptoms (Hewlett et al 1992). 
Generally, SSRIs antidepressants tend to be preferred 
over tricyclic antidepressants in treating anxiety disorders 
including OCD (Simpson et al 2004), a practice due to, in 
part, overall fewer side  effects from SSRIs (Starcevic 2005). 
In placebo-controlled trials, citalopram, ﬂ  uoxetine, ﬂ  uvox-
amine, paroxetine, and sertraline all appear effective in the 
short-term treatment of OCD (Fallon and Mathew 2000; Eddy 
et al 2004), and the SSRIs as a class are generally considered 
to be ﬁ  rst-line drug treatment for OCD (Kaplan and Hollander 
2003; Simpson et al 2004; Stein, Tonnoir et al 2007), despite 
the slight possible superiority of clomipramine in efﬁ  cacy 
studies (Dell’Osso et al 2006). Case reports, open trials, and 
blinded trials comparing venlafaxine with active comparators 
preliminarily support the efﬁ  cacy of venlafaxine (Phelps and 
Cates 2005), a dual serotonin and norepinephrine reuptake 
inhibitor, for OCD. However, a placebo-controlled trial of 
venlafaxine in OCD did not show clear superiority for ven-
lafaxine (Phelps and Cates 2005). As such, more controlled 
trials are required to establish the place of venlafaxine in the 
treatment of OCD (Dell’Osso et al 2006). 
Even with the efﬁ  cacy of behavioral interventions and 
SSRIs, many patients with OCD continue to have OCD 
features (Fallon and Mathew 2000; Eddy et al 2004). 
Furthermore, OCD treatment outcome data for over a year 
are limited (Eddy et al 2004). To successfully treat OCD, 
long-term treatment appears to be required due to the chronic 
nature of OCD. For example, Simpson et al (2004) in a 
randomized trial investigated relapse rates after treatment 
discontinuation in patients who had responded to expo-
sure and response therapy alone, to exposure and response 
therapy plus clomipramine, to clomipramine alone, and to 
placebo. They found a signiﬁ  cant advantage at 12 weeks 
after treatment discontinuation for patients who had initially 
responded to exposure and response prevention alone or 
with clomipramine compared with clomipramine alone. In 
other words, successful drug treatment for OCD for many 
patients may require long-term treatment. Moreover, despite 
the use of SSRIs and psychotherapy, refractory OCD remains 
a particular challenge (McDougle et al 1993), resulting in 
several augmentation strategies.
One approach to managing treatment-resistant OCD is 
adding drugs that increase serotonin transmission to SSRIs 
(McDougle et al 2000). Clomipramine, for instance, has 
been combined with SSRIs, although this combination is 
poorly studied and requires careful monitoring of plasma 
clomipramine and desmethylclomipramine levels (Fallon and 
Mathew 2000). Drugs in addition to clomipramine have been 
added to SSRIs in refractory cases. However, a double-blind 
trial found little advantage using lithium to augment ﬂ  uvox-
amine in treatment-resistant OCD (McDougle et al 1991). 
Similarly, McDougle et al (1993) in a placebo-controlled 
trial found little advantage when buspirone was added to ﬂ  u-
voxamine in patients who had not responded to ﬂ  uvoxamine 
alone. Other drugs that have been combined with an SSRI in 
an attempt to improve response in OCD include donepezil 
and gabapentin (Fallon and Mathew 2000), although these 
trials tended to be small and uncontrolled. The double-blind, 
placebo-controlled addition of the beta blocker pindolol 
to patients who had not responded to open treatment with 
paroxetine resulted in improvement as measured by the Yale-
Brown Obsessive-Compulsive Scale (Dannon et al 2000). In Neuropsychiatric Disease and Treatment 2007:3(4) 457
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contrast, an earlier double-blind, placebo-controlled trial of 
pindolol or placebo in conjunction with ﬂ  uvoxamine showed 
no differences between groups (Mundo et al 1998). 
A second approach to treatment refractory OCD outlined 
by McDougle et al (2000) includes the use of low-dose 
dopamine antagonists added to existing regimens of SSRIs. 
Second-generation antipsychotics, for example, may improve 
the treatment response when added to an SSRI that is only 
producing a partially favorable response (Starcevic 2005). 
In a double-blind, placebo-controlled trial, McDougle et al 
(2000) found that low-dose risperidone was effective in 
reducing OCD features when added to an SSRI. Similarly, 
in a double-blind, placebo-controlled study of treatment-
refractory subjects with OCD already taking ﬂ  uoxetine, 
paroxetine, sertraline, or clomipramine, Bystritsky et al 
(2004) reported that the addition of the second-generation 
antipsychotic olanzapine to an SSRI in a double-blind, 
randomized trial was superior to the placebo group. Some 
controlled evidence supports the use of intravenous clomip-
ramine for treatment-refractory OCD (Fallon and Mathew 
2000). Finally, in some severe, treatment-refractory cases, 
stereotactic cingulotomy or other neurosurgical intervention 
can be associated with improvement in OCD, although these 
procedures tend to be reserved for extreme cases (Chang et al 
2003; Cosgrove and Rauch 2003; Jung et al 2006). 
Despite the use of both psychotherapy and pharmacotherapy 
in OCD, the response to treatment is often suboptimal 
(McDougle et al 1993), even with augmentation techniques 
(Bystritsky et al 2004). In fact, according to some estimates, 
approximately 40% (Dell’Osso et al 2006) to 60% (Fallon and 
Mathew 2000; Pallanti et al 2002) of patients with OCD have 
an inadequate response to SSRIs. Further, even some reduc-
tion in OCD features still may leave patients with consider-
able morbidity (Fallon and Mathew 2000). The prevalence of 
inadequate response to available OCD treatments argues for a 
need to consider alternative approaches to the management of 
OCD. One such potential treatment warranting consideration 
for use in adult OCD is the SSRI escitalopram. 
Pharmacology and mechanism 
of action of escitalopram
The SSRI citalopram is a racemic preparation (Lader et al 
2004) composed of both right (R) and left (S) stereoisomers 
(Burke and Kratochvil 2002) in a 1:1 ratio (Sanchez et al 
2003). However, biochemistry in vivo appears to be enan-
tiomer selective, possibly responding preferentially to only 
one stereoisomer (Burke and Kratochvil 2002), consistent 
with findings that it is the S-enantiomer of citalopram 
(ie, escitalopram) that inhibits serotonin reuptake (Hyttel 
et al 1992). In fact, citalopram’s R-enantiomer appears to 
be relatively inactive (Dhillon et al 2006). Not only may 
it be inactive, but ﬁ  ndings suggest that the R-enantiomer 
of citalopram may actually interfere with the action of the 
S-enantiomer. For example, Sanchez et al (2003) reported 
that R-citalopram signiﬁ  cantly interfered with the anxiolytic-
like effect of escitalopram in an animal model. The interference 
effect of R-citalopram may not extend to other SSRIs, as 
suggested by ﬁ  ndings showing that R-citalopram did not 
appear to inhibit the behavioral effects of ﬂ  uoxetine (Storustovu 
et al 2004). However, ﬁ  ndings showing that R-citalopram 
can interfere with S-citalopram provide a rationale for the 
possibility that S-citalopram could have superior clinical 
efﬁ  cacy compared with citalopram, which contains both 
R and S enantiomers. Moreover, the behavioral effect of 
escitalopram in the fear conditioned stress animal model of 
anxiety was greater than the behavioral effect of the dose-
equivalent racemic preparation of citalopram, an observation 
providing additional evidence that the enantiomer speciﬁ  city 
of escitalopram carries an advantage over citalopram, even 
though citalopram contains escitalopram (Sanchez et al 
2003). Finally, equivalent doses of escitalopram increase 
frontal extracellular serotonin more than does citalopram 
(Baldwin and Nair 2005). 
Used in adults for the treatment of depressive and anxiety 
disorders (Burke 2002), the SSRI escitalopram is simply the 
S-enantiomer of citalopram (Burke and Kratochvil 2002), a 
development designed to take advantage of physiological 
stereoisomer speciﬁ  city by producing a drug preparation 
consisting of only one stereoisomer.
Like other SSRIs, escitalopram initiates its biological 
effects by binding to the serotonin transport molecule (Burke 
2002) and increasing the concentration of serotonin in the 
synapse. A notable feature of escitalopram is that it is the 
most selective of all the SSRIs, having little or no afﬁ  nity 
for 144 other binding sites (Sanchez et al 2003). In addition, 
escitalopram binds to both the primary, high-afﬁ  nity site on 
the serotonin transporter protein, which inhibits serotonin 
reuptake, and to a low-afﬁ  nity site that alters binding at the 
primary site (Dhillon et al 2006). Consistent with ﬁ  ndings 
showing that R-citalopram is relatively inactive (Dhillon et al 
2006), escitalopram binds more than 30 times more potently 
to the serotonin transporter receptor than does R-citalopram 
(Burke 2002), providing further support that stereoisomers 
have biological relevance. Other neurotransmitter receptors 
may be affected differently by R-citalopram and escitalopram. 
For example, Sanchez et al (2003) reported that citalopram Neuropsychiatric Disease and Treatment 2007:3(4) 458
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and R-citalopram have afﬁ  nity for the histamine 1 receptor, 
whereas escitalopram does not. 
It is likely that binding to the serotonin transporter initi-
ates a series of effects in the brain beyond serotonin reuptake 
inhibition. Although little such data exist for escitalopram, 
functional neuroimaging data from citalopram are intriguing. 
In a study using single photon emission computed tomography, 
Carey et al (2004) found that citalopram treatment was 
associated with signiﬁ  cant deactivation in the cingulate 
cortex, right thalamus, and left hippocampus in several 
anxiety disorders including OCD. Citalopram treatment 
may affect other metabolic factors in addition to cerebral 
blood ﬂ  ow. For example, citalopram use in OCD was asso-
ciated with prefrontal and frontal white matter increases in 
N-acetylaspartate (Jang et al 2006), showing that citalopram 
can substantially alter brain function in various brain regions. 
While comparable data for escitalopram are not available, 
escitalopram may well cause cerebral blood-flow and 
metabolic effects similar to those reported with citalopram 
because of the racemic nature of citalopram. 
Pharmacokinetics of escitalopram
In general, the pharmacokinetics of escitalopram appear 
favorable. For instance, the relationship between escitalopram 
dose and plasma concentrations is linear, which allows for 
plasma levels to be predicted from dose (Burke 2002). The 
absorption of escitalopram is not affected by food, and it 
reaches peak serum levels in three to four hours (Baldwin 
and Nair 2005). The half-life of escitalopram varies from 
approximately 27 to 32 hours (Burke 2002), enabling 
once daily dosing and eliminating the need for multiple 
daily doses. In people over age 65 though, the half-life can 
increase to 40 hours (Baldwin and Nair 2005), necessitat-
ing dosage adjustments in the elderly (Dhillon et al 2006). 
Steady state plasma concentrations in healthy volunteers 
occur in 7 to 10 days (Dhillon et al 2006). Like all other 
SSRIs, escitalopram undergoes extensive metabolism by 
cytochrome P450 enzymes, which convert escitalopram to 
S-desmethyl-citalopram and then to S-didesmethyl-citalopram 
(von Moltke et al 2001), neither of which metabolites appear 
to signiﬁ  cantly affect serotonin reuptake (Dhillon, Scott and 
Plosker 2006). An in vitro study found that the cytochrome 
P450 enzymes 2C19, 2D6, and 3A4 accounted for 37%, 28%, 
and 35% respectively of the metabolism of escitalopram (von 
Moltke et al 2001). Drugs that inhibit these enzymes can 
increase escitalopram concentrations (Dhillon et al 2006). 
Compared with some other SSRIs, escitalopram may have 
weak or minimal interactions with the cytochrome P450 
system (von Moltke et al 2001; Burke 2002), reducing the 
potential for cytochrome P450 drug–drug interactions (von 
Moltke et al 2001). In vivo work, in contrast, shows that 
escitalopram can inhibit cytochrome P450 2D6 (Dhillon, Scott 
and Plosker 2006), an effect that requires further study to 
more fully understand escitalopram’s potential for drug-drug 
interactions. 
Escitalopram efﬁ  cacy studies
To date, escitalopram has shown efﬁ  cacy in adult major 
depression (Burke 2002; Burke et al 2002), a condition 
in which it may have a faster antidepressant response 
than citalopram (Lepola et al 2003). A number of rela-
tively short-term trials have found that escitalopram has 
efﬁ  cacy for social anxiety disorder, panic disorder, and 
generalized anxiety disorder (Burke 2002). For example, 
in a double-blind, placebo-controlled trial over 12 and 
24 weeks, Lader et al (2004) found escitalopram to be 
superior to placebo for the management of social anxiety 
disorder. Similarly, Kasper et al (2005) found escitalopram 
in a double-blind, placebo-controlled, randomized trial to 
be superior to placebo in social anxiety disorder, despite a 
high placebo response in this study. Investigating generalized 
social anxiety disorder in a double-blind, placebo-controlled, 
randomized trial, Montgomery et al (2005) found escitalo-
pram to be effective and well tolerated over a 24 week study. 
Another double-blind, placebo-controlled study also found 
escitalopram to be effective in generalized anxiety disorder, 
with discontinuation rates from escitalopram not signiﬁ  cantly 
different from those from placebo (Davidson et al 2004). In 
their review of the use of escitalopram for the treatment of 
generalized anxiety disorder, Baldwin and Nair (2005) note 
that escitalopram has shown efﬁ  cacy in generalized anxiety 
for up to 6 months. 
Despite findings that escitalopram appears to have 
efﬁ  cacy in several anxiety disorders, little work so far has 
examined directly the efﬁ  cacy of escitalopram in OCD. 
Several case reports suggest that escitalopram may be 
effective for conditions having either obsessive features or 
argued by some researchers to be related to OCD (Hollander, 
Friedberg, Wasserman et al 2005). For instance, in a case 
report of a 15-year-old male with transvestic fetishism 
thought by the authors to have a compulsive quality, the addi-
tion of escitalopram resulted in diminished recurrent thoughts 
(Praharaj 2004). Another case report found escitalopram use 
in a 10-year-old boy to be associated with a reduction of 
trichotillomania (Bhatia and Sapra 2004), a condition that 
shares some similarities with OCD and may be part of an Neuropsychiatric Disease and Treatment 2007:3(4) 459
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obsessive-compulsive spectrum (Hollander et al 2005). In an 
open-label trial followed by double-blind discontinuation of 
pathological gambling with anxiety, escitalopram appeared 
effective (Grant and Potenza 2006). Kirkcaldy et al (2004) 
reported a case of obsessive-compulsive disorder charac-
terized by compulsive vomiting that appeared to respond 
favorably to escitalopram. 
Stein et al (2006) conducted the only reported random-
ized, double-blind, placebo-controlled trial of escitalopram in 
OCD, a study that also included the active comparison drug 
paroxetine. After randomization to ﬁ  xed doses of escitalo-
pram 10 mg/day (n = 113), escitalopram 20 mg/day (n = 114), 
paroxetine 40 mg/day (n = 117), or placebo (n = 114) for 
24 weeks, no signiﬁ  cant differences in drop-out rates were 
found between the four groups, although fewer people 
dropped out of the two escitalopram groups compared with 
those dropping out of the placebo and paroxetine groups. In 
terms of efﬁ  cacy, at 12 weeks, the escitalopram 20 mg/day 
group and paroxetine groups were superior to placebo, and 
the escitalopram 10 mg/day group was superior to placebo, 
albeit with a p value of only 0.052. Compared with placebo, 
week 12 effect sizes were 0.43 and 0.33 for escitalopram 
20 mg/day and paroxetine, respectively. By week 24, both 
escitalopram groups and the paroxetine group were signiﬁ  -
cantly superior to placebo in terms of treatment response 
rates. An analysis of remission, deﬁ  ned as a score on the 
Yale-Brown Obsessive-Compulsive Scale of less than or 
equal to 10, showed that only the escitalopram 20 mg group 
was reliably better than placebo in direct comparison to 
paroxetine 40 mg, 
Comparing relapse rates in a large, multi-center study 
in OCD patients who had responded to 16 weeks of open-
label treatment with escitalopram followed by randomized, 
double-blind treatment with either escitalopram (ﬁ  xed dose 
of 10 or 20 mg) or placebo for up to an additional 24 weeks, 
Fineberg et al (2007) found that escitalopram doses at 10 and 
20 mg daily were superior to placebo in preventing relapse. 
Drop-out rates not related to relapse were similar between the 
escitalopram and placebo groups. At the end of the open-label 
part of the study, the response rate (deﬁ  ned by a decrease 
in the Yale-Brown Obsessive-Compulsive Scale of greater 
than or equal to 25%) was 74%. 
Escitalopram safety and tolerability
Both short- and long-term outcome are important when 
evaluating a drug for OCD (Starcevic 2005; Fineberg et al 
2007). As such, drug tolerability requires careful consid-
eration when evaluating a drug’s role in the treatment of a 
disorder, particularly a chronic disorder such as OCD that 
often entails long-term treatment. One method of assessing 
tolerability is to evaluate discontinuation rates due to adverse 
effects in clinical trials. On this count, discontinuation from 
escitalopram in some trials tends to be approximately the 
same as discontinuation rates from placebo (Burke 2002; 
Fineberg et al 2007). Nonetheless, escitalopram is associated 
with several adverse effects that potentially can decrease a 
patient’s quality of life, including dry mouth, insomnia, dif-
ﬁ  culty with ejaculation, nausea, diarrhea, drowsiness (Burke 
2002), yawning (Lader et al 2004), fatigue, headache, dizzi-
ness, and increased sweating (Montgomery et al 2005). 
Montgomery et al (2005) found more adverse effects 
early in their study of escitalopram for generalized social 
anxiety disorder than later in the study, implying the pos-
sibility that tolerance may occur to escitalopram’s adverse 
effects. Furthermore, when these authors excluded adverse-
effect data from the ﬁ  rst two weeks of their study, they found 
that adverse effects were similar overall in the escitalopram 
and placebo groups. 
Analyzing data for escitalopram tolerability in general-
ized anxiety disorder over six months of treatment (Davidson 
et al 2004), Baldwin and Nair (2005) found that the most 
commonly reported adverse effects were headache (25.5%), 
ejaculation disorder (16%), upper respiratory tract infection 
(15.4%), nausea (15.2%), and insomnia (14.8%). Baldwin 
and Nair (2005) concluded that in generalized anxiety 
disorder, escitalopram was better tolerated overall than par-
oxetine. Finally, withdrawal from escitalopram appears to be 
less severe than withdrawal from paroxetine (Montgomery 
et al 2005).  
Conclusion – role of escitalopram 
in OCD
Based on currently available ﬁ  ndings, few studies have 
evaluated the use of escitalopram in OCD and only one 
placebo-controlled, randomized study was conducted, limit-
ing the conclusions that can be drawn about the efﬁ  cacy of 
escitalopram in OCD. Several factors, however, suggest that 
escitalopram may have considerable clinical potential in the 
treatment of adult OCD. First, it is an SSRI, like other drugs 
that are considered to be ﬁ  rst-line drug treatments for OCD 
(Eddy et al 2004). Second, escitalopram may possess unique 
advantages compared with other SSRIs in that it consists 
of not a racemic mixture but rather only the S isomer, a 
preparation that may target the organization of the nervous 
system more speciﬁ  cally than a racemic mixture. Third, 
escitalopram is the most selective of the SSRIs (Sanchez Neuropsychiatric Disease and Treatment 2007:3(4) 460
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et al 2003). Fourth, escitalopram has shown efﬁ  cacy in 
other anxiety disorders including social anxiety disorder, 
panic disorder, and generalized anxiety disorder (Dhillon et 
al 2006). More importantly, the one well-designed, double-
blind, placebo-controlled trial to date of escitalopram in OCD 
(Stein et al 2007) found that escitalopram was superior to 
placebo for the treatment of OCD. Finally, the evidence to 
date suggests that escitalopram is reasonably well tolerated 
and has favorable pharmacokinetics, important features for 
a drug used to treat a highly chronic condition. Nonethe-
less, given the few randomized, placebo-controlled trials of 
escitalopram for OCD to date, the role of escitalopram in 
the treatment of this condition will be better deﬁ  ned by data 
from additional controlled trials. Clearly, more clinical data 
are needed before the role of escitalopram in OCD can be 
deﬁ  ned. In addition to its clinical potential for the treatment 
of OCD, escitalopram may offer theoretical insight into the 
role of stereo-speciﬁ  c enantiomers in OCD. Together, these 
factors provide a rationale for additional trials of escitalopram 
in OCD. To further understand the role of escitalopram in 
the treatment of OCD, more data are required to evaluate 
its use with behavioral interventions such as exposure and 
response prevention treatment. Of equal importance is a 
better understanding of the role of escitalopram in the long-
term treatment of OCD. 
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